Atlas Trials

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Clinical trial NCT01855828 · COMPLETED

Trial details

NCT number
NCT01855828
Sponsor
Yale University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Her2-Positive Breast Cancer
Start date
2013-09-01
Primary completion
2018-08-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.